Priming integrin alpha 5 promotes the osteogenic differentiation of human periodontal ligament stem cells due to cytoskeleton and cell cycle changes

Wang, He; Li, Jianjia; Zhang, Xiaoyi; Ning, Tingting; Ma, Dandan; Ge, Yihong; Xu, Shuaimei; Hao, Yilin; Wu, Buling

doi:10.1016/j.jprot.2018.03.008

Cited by 28 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we confirmed the role of FN1 as a hub gene. Furthermore, integrin plays a role in transmitting information from the ECM to cells, thus participating in cell cycle regulation and cell movement [52][53][54]. Our study found that COL8A1 plays a role in breast cancer.…”

Section: Discussionmentioning

confidence: 51%

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Wei

Zeng

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: The situation faced by breast cancer patients, especially those with triple-negative breast cancer, is still grave. More effective therapeutic targets are needed to optimize the clinical management of breast cancer. Although collagen type VIII alpha 1 chain (COL8A1) has been shown to be downregulated in BRIP1-knockdown breast cancer cells, its clinical role in breast cancer remains unknown. Methods: Gene microarrays and mRNA sequencing data were downloaded and integrated into larger matrices based on various platforms. Therefore, this is a multi-centered study, which contains 5048 breast cancer patients and 1161 controls. COL8A1 mRNA expression in breast cancer was compared between molecular subtypes. In-house immunohistochemistry staining was used to evaluate the protein expression of COL8A1 in breast cancer. A diagnostic test was performed to assess its clinical value. Furthermore, based on differentially expressed genes (DEGs) and coexpressed genes (CEGs) positively related to COL8A1, functional enrichment analyses were performed to explore the biological function and potential molecular mechanisms of COL8A1 underlying breast cancer. Results: COL8A1 expression was higher in breast cancer patients than in control samples (standardized mean difference = 0.79; 95% confidence interval [CI] 0.55-1.03). Elevated expression was detected in various molecular subtypes of breast cancer. An area under a summary receiver operating characteristic curve of 0.80 (95% CI 0.76-0.83) with sensitivity of 0.77 (95% CI 0.69-0.83) and specificity of 0.70 (95% CI 0.61-0.78) showed moderate capacity of COL8A1 in distinguishing breast cancer patients from control samples. Worse overall survival was found in the higher than in the lower COL8A1 expression groups. Intersected DEGs and CEGs positively related to COL8A1 were significantly clustered in the proteoglycans in cancer and ECM-receptor interaction pathways. Conclusions: Elevated COL8A1 may promote the migration of breast cancer by mediating the ECM-receptor interaction and synergistically interplaying with DEGs and its positively related CEGs independently of molecular subtypes. Several genes clustered in the proteoglycans in cancer pathway are potential targets for developing effective agents for triple-negative breast cancer.

show abstract

Section: Discussionmentioning

confidence: 51%

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Wei

Zeng

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Therefore, several studies mixed human PDL-MSCs with HA/TCP and transplanted them into immunodeficient mice. They showed the successful formation of PDL-, bone-, and cementum-like tissues around the HA/TCP scaffold [ 46 , 47 ]. Interestingly, a report demonstrated the formation of Sharpey's fiber-like tissue between PDL and cementum under similar conditions, indicating the complete regeneration of PDL tissues [ 48 ].…”

Section: Introductionmentioning

confidence: 99%

Detection, Characterization, and Clinical Application of Mesenchymal Stem Cells in Periodontal Ligament Tissue

Tomokiyo

Yoshida

Hamano

et al. 2018

Stem Cells International

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are a kind of somatic stem cells that exert a potential to differentiate into multiple cell types and undergo robust clonal self-renewal; therefore, they are considered as a highly promising stem cell population for tissue engineering. MSCs are identified in various adult organs including dental tissues. Periodontal ligament (PDL) is a highly specialized connective tissue that surrounds the tooth root. PDL also contains MSC population, and many researchers have isolated them and performed their detailed characterization. Here, we review the current understanding of the features and functions of MSC population in PDL tissues and discuss their possibility for the application of PDL regeneration.

show abstract

“…Here we have found that IOs and MF significantly upregulated the expression of INTa-3 and INTa-5. Interestingly, INTa-3 is involved in fibronectin deposition into pericellular matrix [44] while INTa-5 was shown to promote the osteogenic differentiation of human periodontal ligament stem cells [45]. Also it was shown that INTa-5 expression increase during osteogenesis progression [46].…”

Section: Discussionmentioning

confidence: 99%

Iron oxides nanoparticles (IOs) exposed to magnetic field promote expression of osteogenic markers in osteoblasts through integrin alpha-3 (INTa-3) activation, inhibits osteoclasts activity and exerts anti-inflammatory action

Marycz¹,

Sobierajska²,

Roecken³

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

Background: Prevalence of osteoporosis is rapidly growing and so searching for novel therapeutics. Yet, there is no drug on the market available to modulate osteoclasts and osteoblasts activity simultaneously. Thus in presented research we decided to fabricate nanocomposite able to: (i) enhance osteogenic differentiation of osteoblast, (i) reduce osteoclasts activity and (iii) reduce pro-inflammatory microenvironment. As a consequence we expect that fabricated material will be able to inhibit bone loss during osteoporosis. Results:The α-Fe 2 O 3 /γ-Fe 2 O 3 nanocomposite (IOs) was prepared using the modified sol-gel method. The structural properties, size, morphology and Zeta-potential of the particles were studied by means of XRPD (X-ray powder diffraction), SEM (Scanning Electron Microscopy), PALS and DLS techniques. The identification of both phases was checked by the use of Raman spectroscopy and Mössbauer measurement. Moreover, the magnetic properties of the obtained IOs nanoparticles were determined. Then biological properties of material were investigated with osteoblast (MC3T3), osteoclasts (4B12) and macrophages (RAW 264.7) in the presence or absence of magnetic field, using confocal microscope, RT-qPCR, western blot and cell analyser. Here we have found that fabricated IOs: (i) do not elicit immune response; (ii) reduce inflammation; (iii) enhance osteogenic differentiation of osteoblasts; (iv) modulates integrin expression and (v) triggers apoptosis of osteoclasts. Conclusion:Fabricated by our group α-Fe 2 O 3 /γ-Fe 2 O 3 nanocomposite may become an justified and effective therapeutic intervention during osteoporosis treatment.

show abstract

Priming integrin alpha 5 promotes the osteogenic differentiation of human periodontal ligament stem cells due to cytoskeleton and cell cycle changes

Cited by 28 publications

References 34 publications

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Detection, Characterization, and Clinical Application of Mesenchymal Stem Cells in Periodontal Ligament Tissue

Iron oxides nanoparticles (IOs) exposed to magnetic field promote expression of osteogenic markers in osteoblasts through integrin alpha-3 (INTa-3) activation, inhibits osteoclasts activity and exerts anti-inflammatory action

Contact Info

Product

Resources

About